PRLD
Prelude Therapeutics Inc
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Prelude Therapeutics Inc
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No thesis.
Fund move
Fund move
Prelude Therapeutics Inc
3.89
−0.21 · −5.01%
post 3.89 0.00%
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | Orbimed AdvisorsOrbimed | $73.2M | 27.50% | +25.81% | |
| 2 | Baker Bros. AdvisorsBaker Bros. | $54.0M | 20.29% | 0.00% | |
| 3 | RA Capital ManagementRA Capital Management | $34.5M | 12.98% | new | |
| 4 | Soleus Capital ManagementSoleus | $18.0M | 6.77% | new | |
| 5 | Kynam Capital ManagementKynam | $12.9M | 4.84% | +51.65% | |
| 6 | Vanguard Capital ManagementVanguardindex-like | $10.7M | 4.03% | +63.32% | |
| 7 | BlackRockBlackRockindex-like | $9.6M | 3.60% | +458.43% | |
| 8 | Sphera Funds ManagementSphera Funds | $5.4M | 2.04% | +82.65% | |
| 9 | Two Sigma InvestmentsTwo Sigma | $5.3M | 1.99% | +7.55% | |
| 10 | ADAR1 Capital ManagementADAR1 | $4.8M | 1.81% | +489.50% | |
| 11 | Millennium ManagementMillennium | $4.5M | 1.69% | +120.78% | |
| 12 | Geode Capital ManagementGeodeindex-like | $4.5M | 1.69% | +178.34% | |
| 13 | Adage Capital Partners GPAdage Capital Partners GP | $4.1M | 1.54% | new | |
| 14 | Acadian Asset ManagementAcadian | $3.3M | 1.23% | +19.52% | |
| 15 | Morgan StanleyMorgan Stanley | $2.7M | 1.01% | +56.40% | |
| 16 | State StreetState Streetindex-like | $2.3M | 0.86% | +210.20% | |
| 17 | UBS GroupUBS | $1.7M | 0.64% | +394.22% | |
| 18 | Vanguard Fiduciary TrustVanguard Fiduciary Trustindex-like | $1.5M | 0.57% | new | |
| 19 | Renaissance TechnologiesRenaissance Technologies | $1.5M | 0.56% | +2.18% | |
| 20 | Northern TrustNorthern Trustindex-like | $1.3M | 0.48% | +380.05% | |
| 21 | Vanguard Portfolio ManagementVanguard Portfolioindex-like | $1.0M | 0.39% | new | |
| 22 | Marshall WaceMarshall Wace | $1.0M | 0.38% | −46.87% | |
| 23 | Susquehanna International GroupSusquehanna International | $931,151 | 0.35% | −39.51% | |
| 24 | Connor, Clark & Lunn Investment ManagementConnor, Clark & Lunn | $669,480 | 0.25% | +15.15% | |
| 25 | Goldman Sachs GroupGoldman Sachs | $644,045 | 0.24% | −48.90% |
77 managers report $266.0M of Prelude Therapeutics on form 13F for the quarter ended Jun 30 '26. 7 of them hold 80% of it; Orbimed is largest at 27.50%.
Linked news
Expected move
No implied move.
No implied move.
No implied move.